Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01889 (ankylosing spondylitis)
 5,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fenoprofen1 (dl-2-[3-phenoxyphenyl]propionic acid) is a new non-steroidal anti-inflammatory, antipyretic, analgesic agent advocated for use in rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and gout. Published data suggest that in rheumatoid arthritis, fenoprofen 2.4 g daily is comparable in effectiveness with moderate doses of aspirin (3.6 to 4 g daily), but generally causes fewer and milder side-effects at the dosages used. In published comparisons with other non-steroidal anti-inflammatory agents of the same chemical group, it is closely comparable with naproxen in effectiveness but tends to cause more minor side-effects than naproxen. However, as no one of the non-steroidal anti-inflammatory agents is the most suitable drug for all patients requiring such therapy, fenoprofen should be considered along with the other drugs of its type in the initial treatment of the arthritic patient. Fenoprofen has compared favourably with phenylbutazone in osteoarthrosis of the hips and with aspirin in osteoarthrosis of the shoulders, hips, knees and spine. Its exact place in the management of gout and ankylosing spondylitis remains to be determined.
 ...
PMID:Fenoprofen: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. 32 48

Naproxen is a propionic acid derivative with analgesic and anti-inflammatory activity which has been widely used in the treatment of rheumatic diseases. Naproxen has been well studied in rheumatoid arthritis and is as effective as aspirin but better tolerated, thus enabling more patients to continue with treatment. For this reason some clinicians now prefer to try propionic acid derivatives, such as naproxen, before aspirin in arthritic patients. In comparative studies with other non-steroidal anti-inflammatory drugs, such as indomethacin, ibuprofen, fenoprofen and others, all drugs were usually of similar overall efficacy although naproxen was sometimes preferred: but as with other non-steroidal anti-inflammatory agents, not all patients will respond to naproxen and in such cases other agents should also be tried until the most satisfactory drug is found for each patient. Naproxen is also effective in degenerative joint diseases of the hip and knee, although further well designed studies are needed to more clearly define its relative place compared with newer drugs such as diclofenac or diflunisal. Results of other comparative studies have shown that naproxen is a suitable alternative to phenylbutazone or indomethacin in ankylosing spondylitis and to aspirin in juvenile rheumatoid arthritis. Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea. Naproxen has generally been better tolerated than aspirin or indomethacin at the dosages used. Because of its relatively long plasma half-life, naproxen can with convenieice be given twice daily, and there is some evidence that once daily dosage is as effective in rheumatoid arthritis.
 ...
PMID:Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. 38 72

The methodology of documenting clinical findings and statistical analysis of the results of a multicentre double-blind cross-over study, in which the efficacy of d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) and indometacin in the treatment of rheumatic diseases was compared, is presented. Eight investigators from four clinics conducted this clinical trial according to an identical protocol in a total of 100 patients. 46 patients (5 male and 31 female) with rheumatoid arthritis received either of the two drugs over a period of 26 days. 35 patients (32 male and 3 female) with ankylosing spondylitis and 19 patients (8 male and 11 female) with osteoarthrosis were treated with either of the drugs for 15 days. The following parameters were investigated and documented: pain and its localization, inhibition of joint function, symptoms of inflammation, and the "quasi" irreversible joint changes. These various parameters were for statistical purposes combined as indices for pain, function, and inflammation. This permitted a quantitative evaluation of the analgesic and antiinflammatory efficacy as well as of the improvement of joint function of the two compounds tested. The overall results of the clinical parameters revealed no significant difference in efficacy for the two drugs. When differentiating the patients as to their sex, both drugs showed higher efficacy in male patients, and only slight efficacy in female patients.
 ...
PMID:[Methods and statistics of multicentral double-blind "cross-over" examination of naproxen compared to indomethacin]. 109 2

In a multicenter double-blind cross-over trial the therapeutic effect and the tolerance of d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) and indometacin were compared including 46 patients with rheumatoid arthritis, 35 patients with ankylosing spondylitis and 19 patients with osteoarthrosis. Duration of treatment with both drugs was two to four weeks each. The daily dose of naproxen was 750 mg, that of indometacin l50 mg. In rheumatoid arthritis the combined clinical effect of indometacin was stronger than that of naproxen while both drugs had the same clinical effectiveness in ankylosing spondylitis and osteoarthrosis. When differentiating the total clinical effect as to indices of pain, inflammation and function, indometacin was shown to be superior in all three diseases with regard to pain index. On the other hand, naproxen showed a better effect in ankylosing spondylitis and osteoarthrosis than indometacin as to inflammation, and as to function in osteoarthrosis.
 ...
PMID:[Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis]. 109 3

27 patients with ascertained ankylosing spondylitis experiencing constant after-midnight-pain received, following three medication-free days, in a double blind, randomized, cross-over fashion indometacin (100 g/day) and d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) (500 mg/day), as suppositories, for a period of six days each. The intensity of the night-pain was recorded daily. Naproxen was shown to be equally effective as indometacin in alleviating the after-midnight backache of ankylosing spondylitis. Side effects occurred under indometacin in 5 cases, under naproxen in 3 cases.
 ...
PMID:[A double blind comparison of naproxen and indomethacin on the after-midnight-pain of patients with morbus bechterew]. 109 4

The need for a nonsteroidal anti-inflammatory agent effective in rheumatoid arthritis, osteoarthritis, gout, ankylosing spondylitis and related diseases with reduced side effects when compared to existing drugs led us to develop naproxen: d-2-(6'-methoxy-2'-naphthyl)-propionic acid. This new agent is a highly effective anti-inflammatory, analgetic, and antipyretic agent in the rodent administered orally. In a rat paw edema test for anti-inflammatory activity naproxen was 55 times more active than aspirin. Analgetic activity was assessed by three different assay procedures. In the mouse phenylquinone writhing test naproxen was 7 times as effective as aspirin. In the rat yeast-induced paw edema and the rat carrageenin paw edema analgetic assays the test compound was 10 and 20 times more effective than aspirin, respectively. A yeast-induced pyresis model in the rat indicated that naproxen was 22 times more potent than the standard aspirin. The relative potency of naproxen to phenylbutazone and indometacin is presented.
 ...
PMID:Chemistry and pharmacology of naproxen. 117 74

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of oxaprozin are reviewed. Oxaprozin, a nonsteroidal anti-inflammatory drug (NSAID) under consideration for approval by the Food and Drug Administration, is characterized as a propionic acid. By inhibiting cyclo-oxygenase, oxaprozin decreases the formation of prostaglandin (PG) precursors from arachidonic acid, resulting in decreased PG biosynthesis and reduced pain and inflammatory responses. Oxaprozin is well absorbed after oral administration, and peak plasma concentration is reached in three to six hours. Oxaprozin is primarily eliminated by urinary excretion of the unchanged drug. It has a long elimination half-life and persists in synovial fluid. In clinical studies, oxaprozin was equally or more effective than aspirin and as effective as naproxen in the treatment of rheumatoid arthritis. For treatment of osteoarthritis, oxaprozin was as effective as naproxen and more effective than aspirin or piroxicam. Studies have also shown oxaprozin to be effective therapy for juvenile rheumatoid arthritis and ankylosing spondylitis. Oxaprozin, like other NSAIDs, can cause gastrointestinal adverse effects. Other possible adverse effects include allergic reactions, analgesic nephropathy, hepatotoxicity, and increased bleeding times. For adults, the anticipated daily dosage is 600-1200 mg given as a single dose for rheumatoid arthritis, osteoarthritis, and analgesia. In children, oxaprozin 10-20 mg/kg/day has been used to treat juvenile rheumatoid arthritis. Oxaprozin is as effective as other NSAIDs and offers once-daily dosing; however, it does not offer any therapeutic advantage over other currently available NSAIDs.
 ...
PMID:Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug. 845 76

A retrospective investigation of the prescription of nonsteroidal antiinflammatory drugs (NSA) was performed in the Rheumatologic out-patient-institute in Zagreb, including 1000 patients of both sexes, aged 20-70 years. 500 outpatients were treated by NSA during 1987 and 1989 respectively for lumbosacral syndrome, rheumatoid arthritis, ankylosing spondylitis and coxarthrosis. The kind of NSA as well as the registered side-effects were analysed from case histories. During 1987, NSA were applied to 365 (73%) and during 1989 to 390 (78%) of the 500 patients. In both groups a phenyl-acetic acid derivative (diclophenac) was most often applied, followed by propionic acid derivatives and oxycams. The most rarely applied drugs were indol-acetic acid derivatives. Pyrazolones were given only to 2 patients with an acute flare of ankylosing spondylitis in 1987. A gastro-duodenal ulcer was the absolute counterindication for this kind of treatment. The number of side-effects in this investigation was relatively small (6.5% in 1987 and 5% in 1989), probably because this investigation was a retrospective one. The most common among them appeared in the gastro-intestinal tract.
 ...
PMID:[Use of non-steroidal antiinflammatory drugs in specialty polyclinic practice]. 249 3